Document Detail

Reversible ototoxicity: a rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male.
MedLine Citation:
PMID:  25093006     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Amphotericin-B, a broad spectrum antifungal agent, has been known to cause adverse effects such as nephrotoxicity and infusion-related side effects such as fever, chills, rigor, and arthralgias. However, ototoxicity as an adverse effect of Amphotericin-B has not yet been reported in medical literature. We here report a case of a reversible form of ototoxicity induced by liposomal Amphotericin-B (L-AmB).
Pc Das; Ramesh Kandel; Kapil Sikka; Ab Dey
Related Documents :
6281716 - Haemorrhagic manifestations with sindbis infection. case report.
19604446 - Visceral leishmaniasis and anti-tnf-alpha therapy: case report and review of the litera...
17114696 - Current knowledge of rickettsial diseases in italy.
6817526 - Murine and epidemic typhus rickettsiae: how close is their relationship?
16941256 - Gallbladder volvulus: review of the literature and report of a case.
12665276 - Non malignant peripheral lymphadenopathy in nigerians.
Publication Detail:
Type:  Journal Article     Date:  2014-07-24
Journal Detail:
Title:  Clinical medicine insights. Case reports     Volume:  7     ISSN:  1179-5476     ISO Abbreviation:  Clin Med Insights Case Rep     Publication Date:  2014  
Date Detail:
Created Date:  2014-08-05     Completed Date:  2014-08-05     Revised Date:  2014-08-07    
Medline Journal Info:
Nlm Unique ID:  101531893     Medline TA:  Clin Med Insights Case Rep     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  63-6     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Personalization of chemotherapy for metastatic pancreatic cancer.
Next Document:  Primary and secondary prevention of colorectal cancer.